Back to top
more

MacroGenics, Inc. (MGNX)

(Delayed Data from NSDQ)

$19.74 USD

19.74
343,208

-0.80 (-3.89%)

Updated Sep 24, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.60%
2Buy19.21%
3Hold10.85%
4Sell6.62%
5Strong Sell3.32%
S&P50011.33%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (215 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Company News for Sep 17, 2021

Companies in The News Are: F,WYNN,LVS,MGNX

MacroGenics (MGNX) Stock Jumps 8.9%: Will It Continue to Soar?

MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -135.71% and -13.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -69.81% and -45.82%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Will MacroGenics (MGNX) Report Negative Earnings Next Week? What You Should Know

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MacroGenics (MGNX) Stock Jumps 6.6%: Will It Continue to Soar?

MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Incyte's (INCY) BLA for Cancer Drug Accepted for Priority Review

Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.

MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 28.26% and 77.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ImmunoGen (IMGN) Q2 Earnings and Sales Beat, Shares Down

ImmunoGen (IMGN) reports encouraging second-quarter results. Top-line data from pivotal study on its lead candidate, mirvetuximab soravtansine, likely to be delayed by six to eight weeks.

MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -6.82% and 42.78%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: MacroGenics (MGNX) Q2 Earnings Expected to Decline

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in MacroGenics (MGNX) Stock?

Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.

MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 9.90% and 84.12%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Ritujay Ghosh headshot

Trump Pushes for US-Made Medical Products: 4 Winners

An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.

ImmunoGen (IMGN) Q1 Earnings and Sales Miss, Shares Down

ImmunoGen (IMGN) reports dismal first-quarter results.

Agios' (AGIO) Q1 Loss Narrower Than Expected, Revenues Beat

Agios' (AGIO) loss and revenues better estimates in Q1. The company's wholly owned leukemia drug Tibsovo sees a sequential rise in sales.

MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 12.68% and 134.54%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 4.21% and -19.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

3 Medical Product Stocks Likely to Beat This Earnings Season

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

MacroGenics (MGNX) Expected to Beat Earnings Estimates: Should You Buy?

MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MacroGenics (MGNX) Reports Q2 Loss, Misses Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 32.29% and -39.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab

Incyte (INCY) inks a licensing deal with Zai Lab to develop and commercialize INCMGA0012 for hematology and oncology indications in Greater China.

Implied Volatility Surging for MacroGenics (MGNX) Stock Options

Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.